1.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
2.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
3.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
4.Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Tsubasa TSUTSUMI ; Dan NAKANO ; Machiko KAWAGUCHI ; Hirokazu TAKAHASHI ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(2):266-268
6.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
7.Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
Saori TAKAMURA ; Yuichi TERAKI ; Eri KATAYAMA ; Takumi KAWAGUCHI ; Machiko KAWAGUCHI ; Dan NAKANO ; Tsubasa TSUTSUMI ; Sumiko NAGOSHI ; Takekuni NAKAMA ; Takuji TORIMURA
Clinical and Molecular Hepatology 2022;28(2):269-272
Result Analysis
Print
Save
E-mail